Get the Stockscreener App
8.81
4.88%
0.41
Pre-market:
8.72
-0.09
-1.02%
Novavax Inc stock is traded at $8.81, with a volume of 3.57M.
It is up +4.88% in the last 24 hours and up +1.26% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
See More
Previous Close:
$8.40
Open:
$8.49
24h Volume:
3.57M
Relative Volume:
0.70
Market Cap:
$1.41B
Revenue:
$793.74M
Net Income/Loss:
$-398.71M
P/E Ratio:
-2.7531
EPS:
-3.2
Net Cash Flow:
$-514.43M
1W Performance:
+3.59%
1M Performance:
+1.26%
6M Performance:
-36.39%
1Y Performance:
+117.53%
1-Day Range:
$8.465
$8.92
1-Week Range:
$8.35
$9.14
52-Week Range:
$3.5324
$23.86
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Compare NVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
8.81 | 1.41B | 793.74M | -398.71M | -514.43M | -3.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax, Inc. (NASDAQ:NVAX) Receives $17.83 Average PT from Analysts - MarketBeat
Novavax, Inc. (NVAX) Stock: The Under-the-Radar Stock Poised for Massive Upside in 2025 - Insider Monkey
10 Under-the-Radar Stocks with Massive Upside for 2025 - Insider Monkey
Novavax climbs as FDA lifts clinical hold on Covid, flu combo trials - MSN
Analysts Set Novavax, Inc. (NASDAQ:NVAX) PT at $17.83 - MarketBeat
Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz - MSN
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Bird Flu Raising Red Flags Among Health Officials, CDC Urges Faster Testing - Benzinga
Moderna Dropped by 20% This Week -- Is It a Smart Buy Right Now? - The Motley Fool
Novavax Cashes In On Its COVID Albatross -- Challenges Remain (Rating Upgrade) - Seeking Alpha
Novavax (NVAX) Rises But Trails Market: What Investors Should Know - Yahoo Finance
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
Novavax Slips 7.3% After 2024 Revenue Guidance Reaffirmed - MarketWatch
Looking Into Novavax's Recent Short Interest - Benzinga
Why Novavax (NVAX) Stock Is Falling - Benzinga
Novavax: presents its 2025 growth strategy - Marketscreener.com
Novavax Shares Strategic Updates at Healthcare Conference - TipRanks
We Asked Retail If Novavax Stock Is A Buy At Current Levels: Nearly 70% Think It's Undervalued - MSN
Novavax to complete data submission to FDA by end of the year for authorization of its coronavirus vaccine - WPSD Local 6
(NVAX) On The My Stocks Page - Stock Traders Daily
Why Novavax Stock Is Volatile This Week - Benzinga
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Novavax (NASDAQ:NVAX) Stock Price Down 8.2%Time to Sell? - MarketBeat
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies - Benzinga
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax (NASDAQ:NVAX) surges 35% this week, taking five-year gains to 171% - Yahoo Finance
Strength Seen in Novavax (NVAX): Can Its 10.9% Jump Turn into More Strength? - MSN
Vaccine Stocks Jump After CDC Reports First US Bird-Flu Death - Yahoo Finance
Health Care Up as Vaccine Makers Surge -- Health Care Roundup - Marketscreener.com
Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid Spike - Yahoo! Voices
Options Alert: Why Novavax (NVAX) Could Be The Biotech Hero Of Trump 2.0 - Barchart
Novavax (NASDAQ:NVAX) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Novavax Target of Unusually High Options Trading (NASDAQ:NVAX) - MarketBeat
Moderna, Novavax Stocks Climb Pre-Market On Growing Bird Flu Concerns: Retail Engagement Soars - MSN
US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally - Benzinga
Novavax (NVAX) Shares Cross Above 200 DMA - Nasdaq
Moderna, Novavax and other vaccine names extend gains amid COVID/flu concerns - Seeking Alpha
Why Novavax (NVAX) Stock Is Rising - Benzinga
Insiders At Novavax Sold US$713k Of Stock Potentially Indicating Weakness - Simply Wall St
Novavax Lowers 2024 Forecast Despite Q3 Revenue Beat, Stock Falls - AOL
Insider Sell: James Young Sells 10,000 Shares of Novavax Inc (NV - GuruFocus.com
Novavax, Inc. (NASDAQ:NVAX) Director James F. Young Sells 4,600 Shares - MarketBeat
Novavax, Inc. (NASDAQ:NVAX) Director James F. Young Sells 5,400 Shares - MarketBeat
Novavax, Inc. (NASDAQ:NVAX) Director Rachel K. King Sells 4,150 Shares - MarketBeat
Novavax director Rachel King sells $37,435 in stock - Investing.com
Novavax director James Young sells shares worth $82,208 - Investing.com
Novavax director Rachel King sells $37,435 in stock By Investing.com - Investing.com UK
Novavax (NASDAQ:NVAX) Trading Up 6.6%Still a Buy? - MarketBeat
NVAX February 14th Options Begin Trading - Nasdaq
Novavax completes $200 million facility sale to Novo Nordisk By Investing.com - Investing.com Australia
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):